Literature DB >> 2699288

Disposition of ethmozine in cerebrospinal fluid and plasma of rabbits.

K Chan1, J M Yang, M K Wai, W D Jiang.   

Abstract

The concentration-time profiles of ethmozine, a newly introduced anti-arrhythmic drug, in the cerebrospinal fluid (CSF) and plasma of six rabbits (New Zealand white rabbits of both sexes, 4.0-5.0 Kg) were studied after intravenous bolus administration. CSF samples at various intervals were obtained while the animal was lightly anaesthetized with intravenous thiopentone (40 mg Kg-1) and blood samples at other intervals were taken while the animal was conscious. Blood samples (1 ml) were collected from the implanted cannula of the ear artery while CSF samples (0.3 ml) were obtained from the cisterna magna. The plasma concentrations of ethmozine in six rabbits declined rapidly after intravenous injection for up to 30 min. then slowly over 12 h. Using non-compartmental analysis, the mean (+/- S.E.M.) elimination half-life, mean residence time, plasma clearance and volume of distribution at steady state were 13.9 +/- 9.2 h, 19.9 +/- 13.4 h, 2.3 Lh-1 and 26.8 +/- 7.9 L respectively. The mean CSF-plasma concentration ratios for ethmozine at 0.5, 1.0, 2.0, 4.0, 8.0 and 12.0 h were 0.17, 0.14, 0.16, 0.16, 0.23 and 0.22 respectively. The results suggest that ethmozine is able to penetrate into the CSF from the general circulation and this may be related to its adverse effects on the central nervous system.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2699288     DOI: 10.1007/BF03190111

Source DB:  PubMed          Journal:  Eur J Drug Metab Pharmacokinet        ISSN: 0378-7966            Impact factor:   2.441


  6 in total

1.  Effects of the phenothiazine analog, EN-313, on ventricular arrhythmias in the dog.

Authors:  P Danilo; W B Langan; M R Rosen; B F Hoffman
Journal:  Eur J Pharmacol       Date:  1977-09-15       Impact factor: 4.432

2.  Ethmozin. I. Effects of intravenous drug administration on paroxysmal supraventricular tachycardia in the ventricular preexcitation syndrome.

Authors:  E I Chazov; K K Shugushev; L V Rosenshtraukh
Journal:  Am Heart J       Date:  1984-09       Impact factor: 4.749

3.  Ethmozin. II. Effects of intravenous drug administration on atrioventricular nodal reentrant tachycardia.

Authors:  E I Chazov; L V Rosenshtraukh; K K Shugushev
Journal:  Am Heart J       Date:  1984-09       Impact factor: 4.749

4.  Ethmozin: a new antiarrhythmic agent developed in the USSR. Efficacy and tolerance.

Authors:  J Morganroth; A S Pearlman; W B Dunkman; L N Horowitz; M E Josephson; E L Michelson
Journal:  Am Heart J       Date:  1979-11       Impact factor: 4.749

5.  Efficacy and safety of moricizine in patients with ventricular tachycardia: results of a placebo-controlled prospective long-term clinical trial.

Authors:  C M Pratt; A Wierman; A A Seals; L English; C Leon; J B Young; M A Quinones; R Roberts
Journal:  Circulation       Date:  1986-04       Impact factor: 29.690

6.  Ethmozine suppression of single and repetitive ventricular premature depolarizations during therapy: documentation of efficacy and long-term safety.

Authors:  C M Pratt; S C Yepsen; A A Taylor; D T Mason; R R Miller; M A Quinones; R A Lewis
Journal:  Am Heart J       Date:  1983-07       Impact factor: 4.749

  6 in total
  1 in total

Review 1.  Moricizine. A review of its pharmacological properties, and therapeutic efficacy in cardiac arrhythmias.

Authors:  A Fitton; M T Buckley
Journal:  Drugs       Date:  1990-07       Impact factor: 9.546

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.